Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.

Van Laere K, De Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, Declercq R, Sanabria Bohorquez SM, Hamill T, Mozley PD, Tatosian D, Xie W, Liu Y, Liu F, Zappacosta P, Mahon C, Butterfield KL, Rosen LB, Murphy MG, Hargreaves RJ, Wagner JA, Shadle CR.

Clin Pharmacol Ther. 2012 Aug;92(2):243-50. doi: 10.1038/clpt.2012.62. Epub 2012 Jun 27.

PMID:
22739139
2.

Pharmacokinetic evaluation of fosaprepitant dimeglumine.

Colon-Gonzalez F, Kraft WK.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1277-86. doi: 10.1517/17425255.2010.513970. Review.

3.

Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.

Van Belle SJ, Cocquyt V.

Expert Opin Pharmacother. 2008 Dec;9(18):3261-70. doi: 10.1517/14656560802548463 . Review.

PMID:
19040346
4.

Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.

Navari RM.

Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42. doi: 10.1586/14737140.8.11.1733. Review.

PMID:
18983233
5.
6.

Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.

Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, Evans JK, Murphy MG.

J Clin Pharmacol. 2007 Jul;47(7):834-40. Epub 2007 May 24.

PMID:
17525168
7.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

8.

Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann CH, Herrstedt J.

Expert Rev Anticancer Ther. 2012 Feb;12(2):139-50. doi: 10.1586/era.11.199. Review.

PMID:
22316362
9.

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.

Bergström M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Långström B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J.

Biol Psychiatry. 2004 May 15;55(10):1007-12.

PMID:
15121485
10.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
11.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J.

J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.

PMID:
21383291
12.

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28.

PMID:
21711119
13.

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.

Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P.

Cancer Chemother Pharmacol. 2012 Dec;70(6):891-8. doi: 10.1007/s00280-012-1967-y. Epub 2012 Oct 9.

PMID:
23053255
14.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
15.

A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.

Maru A, Gangadharan VP, Desai CJ, Mohapatra RK, Carides AD.

Indian J Cancer. 2013 Oct-Dec;50(4):285-91. doi: 10.4103/0019-509X.123580.

16.
17.

Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer.

Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina SB.

Breast Cancer Res Treat. 2016 Apr;156(2):351-9. doi: 10.1007/s10549-016-3747-6. Epub 2016 Mar 11.

18.

Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.

Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, Kodama Y, Miyata Y.

Cancer Chemother Pharmacol. 2008 Dec;63(1):75-83. doi: 10.1007/s00280-008-0713-y. Epub 2008 Mar 4.

PMID:
18317761
19.

A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects.

Shadle CR, Murphy MG, Liu Y, Ho M, Tatosian D, Li SX, Blum RA.

Clin Pharmacol Drug Dev. 2012 Jul;1(3):93-101. doi: 10.1177/2160763X12447304.

PMID:
27121336

Supplemental Content

Support Center